The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.
 
Anne M. Noonan
Consulting or Advisory Role - Exelixis; Helsinn Healthcare; QED Therapeutics
 
Maryam B. Lustberg
Consulting or Advisory Role - Disarm Therapeutics; PledPharma
Other Relationship - Cynosure/Hologic
 
Patrick Schnell
Employment - Syneos Health (I)
Consulting or Advisory Role - Merck
 
John L. Hays
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; Merck; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; Merck; Tesaro
 
Ning Jin
No Relationships to Disclose
 
Laith I. Abushahin
Honoraria - Bionest Partner
Research Funding - Celgene (Inst)
 
Pannaga G. Malalur
No Relationships to Disclose
 
Sameek Roychowdhury
Stock and Other Ownership Interests - Johnson & Johnson (I)
Consulting or Advisory Role - AbbVie; Incyte; Merck; QED Therapeutics
Research Funding - Ignyta; Incyte; QED Therapeutics; Takeda
 
Rifat T. Elkhatib
No Relationships to Disclose
 
Huizi Chen
Honoraria - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Salwan Al Mutar
No Relationships to Disclose
 
Alex Sparreboom
No Relationships to Disclose
 
Shuiying Hu
No Relationships to Disclose